Search results for "gastric"

showing 10 items of 536 documents

MODULATION OF GRO-ALPHA AND TNF-ALPHA PRODUCTION BY PERIPHERAL BLOOD MONONUCLEAR CELLS TREATED WITH KILLED HELICOBACTER PYLORI.

2007

GRO-alpha seems to play an important role in recruiting and activating neutrophils during Helicobacter pylori infection. In the present study, we examined how treatment with killed H. pylori or/and live H. pylori may differentially influence the in vitro GRO-alpha and TNF-alpha release by peripheral blood mononuclear cells (PBMC). The amounts of TNF-alpha and GRO-alpha produced by PBMC after stimulation with live H. pylori were higher than those produced after stimulation with a combination of killed and live H. pylori and the latter were higher than those produced after stimulation with killed H. pylori. In conclusion, the treatment of peripheral blood mononuclear cells with killed H. pyl…

0301 basic medicineEXPRESSIONImmunologyGASTRIC-MUCOSAlcsh:MedicineGASTRIC-MUCOSA; IN-VITRO; CHEMOKINE; GRANULOCYTES; EXPRESSION; INFECTION; SECRETIONGRANULOCYTESPeripheral blood mononuclear cell03 medical and health sciences0302 clinical medicineINFECTIONImmunology and AllergybiologyChemistrylcsh:RIN-VITROHelicobacter pyloribacterial infections and mycosesbiology.organism_classificationMolecular biologyCHEMOKINE030104 developmental biology030220 oncology & carcinogenesisImmunologySECRETIONlipids (amino acids peptides and proteins)
researchProduct

Taste of Fat: A Sixth Taste Modality?

2015

International audience; An attraction for palatable foods rich in lipids is shared by rodents and humans. Over the last decade, the mechanisms responsible for this specific eating behavior have been actively studied, and compelling evidence implicates a taste component in the orosensory detection of dietary lipids [i.e., long-chain fatty acids (LCFA)], in addition to textural, olfactory, and postingestive cues. The interactions between LCFA and specific receptors in taste bud cells (TBC) elicit physiological changes that affect both food intake and digestive functions. After a short overview of the gustatory pathway, this review brings together the key findings consistent with the existence…

0301 basic medicineFood intakeTastePhysiologyLong-Chain FattyAcid Transporter FatGlucagon-Like Peptide-1ReviewBiologyReceptors G-Protein-CoupledFood Preferences03 medical and health sciencesBud CellsRisk Factors2-Bottle Choice TestPhysiology (medical)Obesity-Resistant RatsAnimalsHumansGastric Bypass-SurgeryObesityGustatory pathwayTaste Bud CellsMolecular BiologyModality (semiotics)[ SDV.MHEP.PHY ] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]Fatty AcidsTaste PerceptionFeeding BehaviorGeneral MedicineTaste BudsDietary FatsSweet TasteVasoactive-Intestinal-Peptide030104 developmental biologyOverconsumptionBiochemistryTasteEating behaviorlipids (amino acids peptides and proteins)Digestive functionsReceptor-CellsNeuroscienceSignal Transduction
researchProduct

Association of Long Non-Coding RNA Polymorphisms with Gastric Cancer and Atrophic Gastritis

2020

Long non-coding RNAs (lncRNA) play an important role in the carcinogenesis of various tumours, including gastric cancer. This study aimed to assess the associations of lncRNA ANRIL, H19, MALAT1, MEG3, HOTAIR single-nucleotide polymorphisms (SNPs) with gastric cancer and atrophic gastritis. SNPs were analyzed in 613 gastric cancer patients, 118 patients with atrophic gastritis and 476 controls from three tertiary centers in Germany, Lithuania and Latvia. Genomic DNA was extracted from peripheral blood leukocytes. SNPs were genotyped by the real-time polymerase chain reaction. Results showed that carriers of MALAT1 rs3200401 CT genotype had the significantly higher odds of atrophic gastritis …

0301 basic medicineGastritis AtrophicMalemedicine.medical_specialtylcsh:QH426-470GenotypeAtrophic gastritisSingle-nucleotide polymorphismmedicine.disease_causeGastroenterologyPolymorphism Single NucleotideArticleTertiary Care Centers03 medical and health sciences0302 clinical medicineGene FrequencyStomach NeoplasmsInternal medicineGermanyatrophic gastritisGenotypeGeneticsmedicineOdds RatioHumansGenetic Predisposition to DiseaseRNA NeoplasmGenetics (clinical)AllelesAgedMALAT1long non-coding RNAbusiness.industrylong non-coding RNA ; single-nucleotide polymorphism ; gastric cancer ; atrophic gastritisgastric cancerCancerHOTAIRMiddle Agedsingle-nucleotide polymorphismmedicine.diseaseLong non-coding RNAlcsh:Genetics030104 developmental biology030220 oncology & carcinogenesisFemaleRNA Long NoncodingCarcinogenesisbusinessGenes
researchProduct

The Ciona intestinalis immune-related galectin genes (CiLgals-a and CiLgals-b) are expressed by the gastric epithelium.

2017

The transcription of two Ciona intestinalis galectin genes (CiLgals-a and CiLgalseb) is uparegulated by LPS in the pharynxis (hemocytes, vessel epithelium, endostilar zones) which is retained the main organ of the immunity. In this ascidian, for the first time we show, by immunohistochemistry and in situ hybridization methods, that these two immune-related genes are expressed in the gastric epithelium of naïve ascidians, whereas the galectins appear to be only contained in the intestine columnar epithelium. In addition, according to previous results on the pharynx, the genes are also expressed and galectins produced by hemocytes scattered in the connective tissue surrounding the gut. The ge…

0301 basic medicineLipopolysaccharidesPathologymedicine.medical_specialtyanimal structuresGalectinsSettore BIO/05 - ZoologiaConnective tissueIn situ hybridizationAquatic Science03 medical and health sciencesDownregulation and upregulationGene expressionotorhinolaryngologic diseasesmedicineGalectin genes expression Ascidians Ciona intestinalis Gastric and intestine epithelia Hemocytes in the connective tissue Immunolocalization In situ hybridizationEnvironmental ChemistryAnimalsCiona intestinalisIntestinal MucosaGeneIn Situ HybridizationGalectin030102 biochemistry & molecular biologybiologyGeneral Medicinebiology.organism_classificationImmunohistochemistryEpitheliumCell biologyCiona intestinalis030104 developmental biologymedicine.anatomical_structurePharynxFishshellfish immunology
researchProduct

Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model

2016

BACKGROUND & AIMS No published study to date has provided a careful analysis of the effects of a sustained viral response (SVR) on the outcomes of patients with compensated hepatitis C virus (HCV)-related cirrhosis in relation to the degree of portal hypertension. Therefore, we estimated the impact of achieving SVR on disease progression, hepatocellular carcinoma (HCC) development and mortality in a large cohort of HCV patients with cirrhosis with or without oesophageal varices (OVs) at the start of antiviral therapy. METHODS A total of 535 Caucasian patients were prospectively recruited to this study. All patients had a clinical or histological diagnosis of compensated HCV-related cirrhosi…

0301 basic medicineLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularSVRSustained Virologic ResponseHepatitis C virusHepacivirusmedicine.disease_causeEsophageal and Gastric VaricesGastroenterologyAntiviral Agents03 medical and health sciencesLiver diseasemultistate0302 clinical medicineInternal medicinemedicineHumansProspective StudiesAgedCirrhosiHepatologybusiness.industryLiver Neoplasmsvirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasedigestive system diseases030104 developmental biologyItalyLiverHepatocellular carcinomaHCVDisease Progression030211 gastroenterology & hepatologyFemaleViral hepatitisLiver cancerbusinessViral load
researchProduct

Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.

2021

Background & Aims Transjugular intrahepatic portosystemic shunt (TIPS) implantation is an effective and safe treatment for complications of portal hypertension. Survival prediction is important in these patients as they constitute a high-risk population. Therefore, the aim of our study was to develop an alternative prognostic model for accurate survival prediction after planned TIPS implantation. Methods A total of 1,871 patients with de novo TIPS implantation for ascites or secondary prophylaxis of variceal bleeding were recruited retrospectively. The study cohort was divided into a training set (80% of study patients; n = 1,496) and a validation set (20% of study patients; n = 375). Furth…

0301 basic medicineLiver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentPopulationClinical Decision-MakingSerum Albumin HumanEsophageal and Gastric Varices03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineAscitesmedicineSecondary PreventionHumanseducationAgedRetrospective Studieseducation.field_of_studyFramingham Risk ScoreHepatologyProportional hazards modelbusiness.industryAge FactorsAscitesBilirubinMiddle Agedmedicine.diseasePrognosisSurvival Rate030104 developmental biologyTreatment OutcomeResearch DesignCreatinineCohortPortal hypertension030211 gastroenterology & hepatologyFemalemedicine.symptomPortasystemic Shunt Transjugular IntrahepaticbusinessGastrointestinal HemorrhageTransjugular intrahepatic portosystemic shuntJournal of hepatology
researchProduct

Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.

2019

The aim of this manuscript is to discuss the viewpoint of the European Organisation for Research and Treatment of Cancer (EORTC) Gastric Cancer Taskforce and Japan Clinical Oncology Group (JCOG) Gastric Cancer Study Group on the current challenges in the multidisciplinary management of stage II-III gastric and gastro-oesophageal junction (GEJ) cancer. We seek to outline how these challenges are addressed in current trials of both groups. Key elements of future trials of EORTC and JCOG in this indication are described, and a joint vision on how multidisciplinary research of gastric and GEJ cancer patients should be organised is outlined. ispartof: EUROPEAN JOURNAL OF CANCER vol:124 pages:67-…

0301 basic medicineMaleCancer ResearchEsophageal NeoplasmsADJUVANT CHEMOTHERAPY0302 clinical medicineEUROPEAN ORGANIZATIONMultidisciplinary approachGastricPerioperativeStage (cooking)AdjuvantClinical OncologyMISMATCH REPAIR DEFICIENCYdigestive oral and skin physiologyGastro oesophageal junctionOPEN-LABELPrognosisJCOGhumanitiesEORTCOncology030220 oncology & carcinogenesisCLINICAL-RESEARCHFemaleImmunotherapyEsophagogastric JunctionRANDOMIZED PHASE-IILife Sciences & Biomedicinemedicine.medical_specialtyStage ii03 medical and health sciencesStomach NeoplasmsmedicineChemotherapyHumansNeoplasm StagingScience & Technologybusiness.industryPERIOPERATIVE CHEMOTHERAPYGeneral surgeryCancerADENOCARCINOMAPLUS OXALIPLATINmedicine.diseaseSurvival Analysisdigestive system diseases030104 developmental biologyNeoplasm stagingbusinessTRIAL DESIGNEuropean journal of cancer (Oxford, England : 1990)
researchProduct

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

2018

Introduction IMAB362 (Zolbetuximab) is a chimeric monoclonal antibody that binds to Claudin-18.2, a target antigen specific to cancer cells. In vitro, IMAB362 mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity; thus, IMAB362 may serve as a potent, targeted immunotherapeutic agent. Methods This first-in-human phase I study enroled adult patients (N = 15) with advanced gastric or gastro-oesophageal junction cancer into five sequential single dose-escalation cohorts (33, 100, 300, 600, and 1000 mg/m2) following a 3 + 3 design. Safety/tolerability, including determination of maximum tolerated dose and recommended phase II dose, were the pr…

0301 basic medicineMaleCancer Researchmedicine.medical_specialtyTime FactorsEsophageal NeoplasmsMaximum Tolerated Dosemedicine.medical_treatmentMedizinGastroenterologyAntibodies Monoclonal/administration & dosage03 medical and health sciences0302 clinical medicineAntineoplastic Agents ImmunologicalPharmacokineticsAntineoplastic Agents Immunological/administration & dosageStomach NeoplasmsInternal medicineGermanymedicineHumansDrug Dosage CalculationsAdverse effectInfusions IntravenousAgedbusiness.industryCancerAntibodies MonoclonalEsophagogastric Junction/drug effectsImmunotherapyMiddle Agedmedicine.diseaseLatviaddc:030104 developmental biologyTreatment OutcomeOncologyTolerabilityResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisToxicityDisease ProgressionFemaleStomach Neoplasms/drug therapyEsophagogastric JunctionEsophageal Neoplasms/drug therapybusinessProgressive disease
researchProduct

Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro…

2018

BACKGROUND: There currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in whom two prior lines of therapy have failed. The randomised, phase III JAVELIN Gastric 300 trial compared avelumab versus physician's choice of chemotherapy as third-line therapy in patients with advanced GC/GEJC. PATIENTS AND METHODS: Patients with unresectable, recurrent, locally advanced, or metastatic GC/GEJC were recruited at 147 sites globally. All patients were randomised to receive either avelumab 10 mg/kg by intravenous infusion every 2 weeks or physician's choice of chemotherapy (paclitaxel 80 mg/m2 on days 1, …

0301 basic medicineMaleEsophageal Neoplasmsmedicine.medical_treatmentchemotherapyGastroenterologyChoice Behaviorlaw.invention0302 clinical medicineRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsClinical endpointMedicinePractice Patterns Physicians'Aged 80 and overHazard ratioAntibodies MonoclonalHematologyMiddle AgedPrognosisChemotherapy regimenAdenocarcinoma MucinousSurvival RateOncology030220 oncology & carcinogenesisFemaleImmunotherapyEsophagogastric Junctionmedicine.drugPD-L1Adultmedicine.medical_specialtyAdolescentPaclitaxelAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDecision Support Techniquesgastro-oesophageal junction cancer03 medical and health sciencesYoung AdultStomach NeoplasmsInternal medicineGastrointestinal TumorsHumansddc:610Survival rateAgedChemotherapybusiness.industrygastric cancerInternational AgenciesOriginal Articlesphase IIICarcinoma PapillaryClinical trialIrinotecanEditor's Choice030104 developmental biologyavelumabNeoplasm Recurrence LocalbusinessCarcinoma Signet Ring CellBiomarkersFollow-Up Studies
researchProduct

MicroRNAs and Drinking : Association between the Pre-miR-27a rs895819 Polymorphism and Alcohol Consumption in a Mediterranean Population

2016

Recently, microRNAs (miRNA) have been proposed as regulators in the different processes involved in alcohol intake, and differences have been found in the miRNA expression profile in alcoholics. However, no study has focused on analyzing polymorphisms in genes encoding miRNAs and daily alcohol consumption at the population level. Our aim was to investigate the association between a functional polymorphism in the pre-miR-27a (rs895819 A>G) gene and alcohol consumption in an elderly population. We undertook a cross-sectional study of PREvención con DIeta MEDiterránea (PREDIMED)-Valencia participants (n = 1007, including men and women aged 67 7 years) and measured their alcohol consumption (to…

0301 basic medicineMaleMicro RNAsMediterranean dietCross-sectional studyPhysiologyAlcoholmiR27aMediterraneanCOLORECTAL-CANCERFUNCTIONAL POLYMORPHISMlcsh:Chemistrychemistry.chemical_compoundPolymorphism (computer science)GenotypeMedicineMolecular geneticslcsh:QH301-705.5SpectroscopyGeneticsRISKeducation.field_of_studyMediterranean RegionalcoholGeneral MedicineMiddle AgedComputer Science ApplicationsmicroRNAsDrinking of alcoholic beveragesSINGLE NUCLEOTIDE POLYMORPHISMSMENDELIAN RANDOMIZATIONMir27aConsum d'alcoholFemaleAlcoholAlcohol DrinkingGenotypePopulationGENETIC VARIANTHEART-DISEASEPolymorphism Single NucleotideCatalysisArticleGenètica molecularInorganic Chemistry03 medical and health sciencesMediterranean cookingUSE DISORDERSmicroRNACuina mediterràniaHumansPhysical and Theoretical ChemistryeducationMolecular BiologyAgedCHINESE POPULATIONbusiness.industryOrganic ChemistrymicroRNAs; alcohol; miR27a; Mediterraneanmedicine.diseaseObesityMicroRNAs030104 developmental biologyCross-Sectional Studieschemistrylcsh:Biology (General)lcsh:QD1-999GASTRIC-CANCER SUSCEPTIBILITYbusiness
researchProduct